Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen

Date
2019
Author
Isenberg, David A.
Pineau, Christian A.
St-Pierre, Yvan
Rahman, Anisur
GINZLER, Ellen M.
Petri, Michelle
Dooley, Mary Anne
Fortin, Paul
GLADMAN, Dafna D.
STEINSSON, Kristjan
Ramsey-Goldman, Rosalind
KHAMASHTA, Munther A.
ARANOW, Cynthia
MACKAY, Meggan
ALARCON, Graciela
MANZI, Susan
Nived, Ola
Jonsen, Andreas
ZOMA, Asad A.
van Vollenhoven, Ronald F.
RAMOS-CASALS, Manuel
RUIZ-IRASTORZA, Giuillermo
Lim, Sam
KALUNIAN, Kenneth C.
KAMEN, Diane L.
Peschken, Christine A.
JACOBSEN, Soren
Askanase, Anca
Sanchez-Guerrero, Jorge
Bruce, Ian N.
COSTEDOAT-CHALUMEAU, Nathalie
Vinet, Evelyne
Inanc, Murat
BAE, Sang-Cheol
Urowitz, Murray B.
Clarke, Ann E.
ROMERO-DIAZ, Juanita
Gordon, Caroline
Mendel, Arielle
HANLY, John G.
WALLACE, Daniel J.
MERRILL, Joan T.
BUYON, Jill
Bernatsky, Sasha
Metadata
Show full item record
Abstract
Objectives To assess the prevalence of combined hormonal contraceptives (CHCs) in reproductive-age women with SLE with and without possible contraindications and to determine factors associated with their use in the presence of possible contraindications.
URI
http://hdl.handle.net/20.500.12627/14602
https://doi.org/10.1093/rheumatology/kez014
Collections